EA
KZR

Ellsworth Advisors’s Kezar Life Sciences KZR Stock Holding History

Ellsworth Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,584
Closed -$214K – 146
2022
Q2 		$214K Sell
2,584
-5
-0.2% -$441 0.09% 131
2022
Q1 		$386K Buy
+2,589
New +$372K 0.14% 113

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Ellsworth Advisors's KZR Position: Q3 2022 in Review

Ellsworth Advisors sold out of Kezar Life Sciences (KZR) in Q3 2022, closing a stake of 2,584 shares — an estimated $214K sold.

Ellsworth Advisors first reported a position in KZR in Q1 2022 and held it in 2 quarters. The position peaked at $386K in Q1 2022. 132 funds tracked by Wall St. Rank hold KZR as of Q3 2022.

  • Ellsworth Advisors reported no remaining Kezar Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Ellsworth Advisors sold 2,584 Kezar Life Sciences shares in Q3 2022, an estimated $214K.
  • Ellsworth Advisors first reported a position in Kezar Life Sciences in Q1 2022 and held it in 2 quarters.
  • Ellsworth Advisors's Kezar Life Sciences position peaked at $386K in Q1 2022.
  • 132 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2022.

Based on Ellsworth Advisors's 13F filing for Q3 2022, filed 20 Oct 2022.